KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Capital Expenditures (2016 - 2025)

Pfizer (PFE) has disclosed Capital Expenditures for 17 consecutive years, with $845.0 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures changed N/A to $845.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.6 billion through Dec 2025, changed N/A year-over-year, with the annual reading at $2.6 billion for FY2025, 9.63% down from the prior year.
  • Capital Expenditures for Q4 2025 was $845.0 million at Pfizer, up from $602.0 million in the prior quarter.
  • The five-year high for Capital Expenditures was $2.2 billion in Q4 2022, with the low at $537.0 million in Q3 2021.
  • Average Capital Expenditures over 5 years is $958.7 million, with a median of $751.0 million recorded in 2022.
  • The sharpest move saw Capital Expenditures skyrocketed 145.93% in 2024, then plummeted 69.78% in 2025.
  • Over 5 years, Capital Expenditures stood at $1.7 billion in 2021, then surged by 30.78% to $2.2 billion in 2022, then tumbled by 53.29% to $1.0 billion in 2023, then skyrocketed by 90.8% to $2.0 billion in 2024, then crashed by 57.58% to $845.0 million in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $845.0 million, $602.0 million, and $618.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.